UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 19, 2013
Stemline Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware (State or Other Jurisdiction of Incorporation) | | 001-35619 (Commission File Number) | | 45-0522567 (IRS Employer Identification No.) |
750 Lexington Avenue
Sixth Floor
New York, New York 10022
(Address of Principal Executive Offices)
(646) 502-2310
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act.
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
o Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security Holders.
The 2013 annual meeting of stockholders of Stemline Therapeutics, Inc. (“Stemline”) was held on June 19, 2013. The following matters were voted on by the stockholders: the election of one director, the ratification of the appointment of Ernst & Young LLP as Stemline’s independent registered public accounting firm for the year ending December 31, 2013, and an amendment to Stemline’s Restated Certificate of Incorporation to increase the Company’s authorized share capital by 11,250,000 shares of common stock.
The vote with respect to the nominee for director is set forth below:
Nominee | | Total Votes For | | Total Votes
Withheld | | Broker Non-Votes | |
Kenneth Zuerblis | | 4,107,696 | | 50,500 | | 1,284,225 | |
The vote with respect to the ratification of the appointment of Ernst & Young LLP as Stemline’s independent registered public accounting firm for the year ending December 31, 2013, is set forth below:
Total Votes For | | Total Votes Against | | Abstention | | Broker Non-Votes | |
5,391,921 | | 500 | | 50,000 | | 0 | |
The vote with respect to an amendment to the Restated Certificate of Incorporation to increase the Company’s authorized share capital by 11,250,000 shares of common stock is set forth below:
Total Votes For | | Total Votes Against | | Abstention | | Broker Non-Votes | |
4,802,536 | | 586,267 | | 53,618 | | 0 | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Stemline Therapeutics, Inc. |
| (Registrant) |
| |
| |
Date: June 25, 2013 | |
| | |
| By: | /s/ Stephen P. Hall |
| | Stephen P. Hall |
| | Chief Accounting Officer |
3
